Near-infrared dye-conjugated hyaluronic acid derivative and contrast agent for optical imaging including them
US-2015374856-A1 · Dec 31, 2015 · US
US10954348B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10954348-B2 |
| Application number | US-201816040871-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 20, 2018 |
| Priority date | Jan 20, 2016 |
| Publication date | Mar 23, 2021 |
| Grant date | Mar 23, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.
Opening claim text (preview).
The invention claimed is: 1. A method for preparing biocompatible nanoparticles, the method comprising: (a) adding to water, at least one material selected from the group consisting of polysaccharides, and a mixture of a polysaccharide and polyethylene glycol to prepare a 0.1% (w/v) to 15% (w/v) solution; and (b) irradiating the solution prepared in step (a) with an electron beam at a dose of 5 to 250 kGy to crosslink the material, wherein the biocompatible nanoparticle is formed exclusively by inter-molecular or intra-molecular crosslinking of at least one selected from the group consisting of a polysaccharide, and a mixture of a polysaccharide and polyethylene glycol, wherein the method excludes the use of a crosslinking agent, a curing agent, an inorganic material, and an organic solvent, wherein the polysaccharide is at least one selected from the group consisting of mannan, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, fructo-oligosaccharides, isomalto-oligosaccharides, inulin, glycogen, amylose, carboxymethyl dextran, beta-glucan, fucoidan, and chondroitin, wherein a size of the nanoparticle is in a range of 1 to 700 nm.
Reserve carbohydrates, e.g. glycogen, inulin, laminarin; Derivatives thereof (not used) · CPC title
Ethers · CPC title
conjugates with carriers being macromolecules · CPC title
Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof · CPC title
Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.